What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday?
Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17. read more
Read More
The Analyst Verdict: Guidewire Software In The Eyes Of 14 Experts
Latest Ratings for GWRE Date Firm Action From To Mar 2022 Wells Fargo Maintains Underweight Dec 2021 BTIG Maintains Buy Oct 2021 B of A Securities Downgrades Neutral Underperform View More Analyst Ratings for GWRE View the Latest Analyst Ratings read more
Expert Outlook: AtriCure Through The Eyes Of 5 Analysts
Latest Ratings for ATRC Date Firm Action From To Feb 2022 Canaccord Genuity Maintains Buy Feb 2022 Needham Maintains Buy Nov 2021 Needham Maintains Buy View More Analyst Ratings for ATRC View the Latest Analyst Ratings read more
Beyond The Numbers: 5 Analysts Discuss Winnebago Industries Stock
Latest Ratings for WGO Date Firm Action From To Jan 2022 CL King Upgrades Neutral Strong Buy Oct 2021 Keybanc Downgrades Overweight Sector Weight Oct 2021 Keybanc Downgrades Overweight Sector Weight View More Analyst Ratings for WGO View the Latest Analyst Ratings read more
Mobileye Gains Analyst Upgrade On 2025 Catalysts, But Profit Delays And Competition Keep Rating Neutral
Mobileye stock surges after BofA analyst upgrades it to Neutral and raises price target from $12 to $19 due to potential contract wins and steady ADAS growth. Latest Ratings for MBLY Date Firm Action From To Apr 2017 Baird Downgrades Outperform Neutral Mar 2017 Piper Sandler Downgrades Overweight Neutral Mar 2017 Goldman Sachs Downgrades Buy…
Why Bitcoin Outperformed Solana, Ethereum In Last Week’s Flash Crash
Bitcoin (CRYPTO: BTC) has notably outperformed altcoins and meme coins over the recent weeks, according to a new report by on-chain data pro read more